Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cardinal Health ( (CAH) ) is now available.
On August 12, 2025, Cardinal Health announced its fourth quarter and fiscal year 2025 financial results, reporting a relatively flat revenue of $60.2 billion for the fourth quarter. However, excluding the impact of a contract expiration, revenue increased by 21%. The company also reported a significant increase in non-GAAP operating earnings and EPS, driven by strong performance across its segments. Additionally, Cardinal Health raised its fiscal year 2026 non-GAAP EPS guidance and announced the acquisition of Solaris Health, a leading urology management services organization, indicating strategic growth and expansion in its specialty solutions segment.
The most recent analyst rating on (CAH) stock is a Hold with a $110.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.
Spark’s Take on CAH Stock
According to Spark, TipRanks’ AI Analyst, CAH is a Neutral.
Cardinal Health’s overall stock score is driven by solid earnings performance and strategic initiatives, offset by financial risks related to negative equity and valuation concerns. Technical indicators suggest short-term caution, while positive earnings and corporate events bolster long-term prospects.
To see Spark’s full report on CAH stock, click here.
More about Cardinal Health
Cardinal Health operates in the healthcare industry, providing pharmaceutical and medical products and services. The company focuses on pharmaceutical distribution and specialty solutions, serving a wide range of healthcare providers.
Average Trading Volume: 2,059,647
Technical Sentiment Signal: Buy
Current Market Cap: $37.63B
For a thorough assessment of CAH stock, go to TipRanks’ Stock Analysis page.